Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34.
- Author:
He-ping KAN
1
;
Yu WANG
;
Yong-fa TAN
;
Jie ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antigens, CD34; metabolism; Antineoplastic Agents; therapeutic use; Female; Humans; Ki-67 Antigen; metabolism; Liver Neoplasms; drug therapy; metabolism; Male; Middle Aged; Niacinamide; analogs & derivatives; therapeutic use; Phenylurea Compounds; therapeutic use
- From: Journal of Southern Medical University 2010;30(8):1930-1934
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic effects of Nexavar on liver cancer and its relation to the expressions of Ki-67 and CD34.
METHODSTwenty-eight patients with liver cancer were treated with Nexavar. The therapeutic efficacy of Nexavar on liver cancer was observed. Liver cancer tissues were examined for the expressions of Ki-67 and CD34 by immunohistochemistry. Microvessel density (MVD) was calculated according to the expression of CD34.
RESULTSOf 28 patients, none achieved a complete response (CR), 12 had a partial response (PR), 7 had stable disease (SD), and 9 progressive disease (PD). The efficacy of Nexavar was associated significantly with Ki-67 expression. The mean MVD count was 346.03-/+146.98 in PR patients, and 89.14-/+45.66 in PD patients. There was a significant difference in MVD between PR and PD patients.
CONCLUSIONThere is a better efficacy of Nexavar in treatment of liver cancer in the patients who had Ki-67-positive expression and high MVD count.
